AbCellera announces pricing of oversubscribed $200 million public offering of common shares and pre-funded warrants. Foto: adobe.stock.com AbCellera Biologics Inc. (Nasdaq: ABCL) ("AbCellera") today announced the pricing of its oversubscribed underwritten public offering of 17,435,897 common shares at a price to the public of $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 shares of its common shares at a price to the public of $9.74999 per pre-funded warrant, which represents the per share public offering price of each common share less the $0.00001 per share exercise price for each pre-funded warrant. The gross proceeds to AbCellera from the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the common shares and pre-funded warrants are being sold by AbCellera. The offering is expected to close on August 14, 2026, subject to the satisfaction of customary conditions. AbCellera intends to use the net proceeds from the offering to fund the continued research, development and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and other general corporate purposes. Jefferies, J.P. Morgan, Cantor, UBS Investment Bank and BMO Capital Markets are acting as joint book-running managers for the offering. The securities described above are being offered pursuant to a shelf registration statement on Form S-3ASR (No. 333-285367) that was filed with the U.S. Securities and Exchange Commission (the "SEC") on February 27, 2025 and automatically became effective upon filing. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A final prospectus supplement related to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and an accompanying prospectus related to the offering may also be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at [email protected]; UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, NY 10010, by email at [email protected]; or BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at [email protected] Diskutieren sie über die enthaltenen Werte. Business Wire (engl.) Autor folgen Verfasst von Letzte Änderung13.08.2026, 06:05 Im Artikel enthaltene Werte

AbCellera Biologics' shares surged 60.3% following positive Phase 2 trial results for ABCL635, its investigational antibody for menopause treatment. A single 600mg subcutaneous dose significantly reduced frequency and severity of moderate-to-severe hot flashes versus placebo over four weeks, whilst demonstrating favourable tolerability. The results position AbCellera as an emerging competitor in the large, underserved non-hormonal menopause therapy market. The company recently completed a $200 million equity offering to fund larger trials for ABCL635 and other programmes. However, investors face substantial risks. AbCellera continues posting widening net losses and remains dependent on future milestones and product revenue. The company's investment narrative projects $27.9 million revenue by 2029, requiring a 25% yearly revenue decline from current levels.